Literature DB >> 21474639

Cystic fibrosis carrier testing in an ethnically diverse US population.

Elizabeth M Rohlfs1, Zhaoqing Zhou, Ruth A Heim, Narasimhan Nagan, Lynne S Rosenblum, Kerry Flynn, Thomas Scholl, Viatcheslav R Akmaev, D Alexa Sirko-Osadsa, Bernice A Allitto, Elaine A Sugarman.   

Abstract

BACKGROUND: The incidence of cystic fibrosis (CF) and the frequency of specific disease-causing mutations vary among populations. Affected individuals experience a range of serious clinical consequences, notably lung and pancreatic disease, which are only partially dependent on genotype.
METHODS: An allele-specific primer-extension reaction, liquid-phase hybridization to a bead array, and subsequent fluorescence detection were used in testing for carriers of 98 CFTR [cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)] mutations among 364 890 referred individuals with no family history of CF.
RESULTS: One in 38 individuals carried one of the 98 CFTR mutations included in this panel. Of the 87 different mutations detected, 18 were limited to a single ethnic group. African American, Hispanic, and Asian individuals accounted for 33% of the individuals tested. The mutation frequency distribution of Caucasians was significantly different from that of each of these ethnic groups (P < 1 × 10⁻¹⁰).
CONCLUSIONS: Carrier testing using a broad mutation panel detects differences in the distribution of mutations among ethnic groups in the US.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21474639     DOI: 10.1373/clinchem.2010.159285

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  28 in total

1.  Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors.

Authors:  Elinor Langfelder-Schwind; Barbara Karczeski; Michelle N Strecker; Joy Redman; Elaine A Sugarman; Christina Zaleski; Trisha Brown; Steven Keiles; Amy Powers; Sumheda Ghate; Rebecca Darrah
Journal:  J Genet Couns       Date:  2013-09-07       Impact factor: 2.537

2.  A young Hispanic with c.1646G>A mutation exhibits severe cystic fibrosis lung disease: is ivacaftor an option for therapy?

Authors:  Sunitha Yarlagadda; Weiqiang Zhang; Himabindu Penmatsa; Aixia Ren; Kavisha Arora; Anjaparavanda P Naren; Fatima Anmol I Khan; Catherine A Donnellan; Saumini Srinivasan; Dennis C Stokes; John C Kappes
Journal:  Am J Respir Crit Care Med       Date:  2012-10-01       Impact factor: 21.405

Review 3.  Genetics of chronic rhinosinusitis: state of the field and directions forward.

Authors:  Joy Hsu; Pedro C Avila; Robert C Kern; M Geoffrey Hayes; Robert P Schleimer; Jayant M Pinto
Journal:  J Allergy Clin Immunol       Date:  2013-04       Impact factor: 10.793

4.  Attitudes and opinions of pregnant women who are not offered cystic fibrosis carrier screening.

Authors:  Liane Ioannou; John Massie; Sharon Lewis; Veronica Collins; Belinda McClaren; Martin B Delatycki
Journal:  Eur J Hum Genet       Date:  2013-11-20       Impact factor: 4.246

Review 5.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

6.  Functional characteristics of L1156F-CFTR associated with alcoholic chronic pancreatitis in Japanese.

Authors:  Shiho Kondo; Kotoyo Fujiki; Shigeru B H Ko; Akiko Yamamoto; Miyuki Nakakuki; Yasutomo Ito; Nikolay Shcheynikov; Motoji Kitagawa; Satoru Naruse; Hiroshi Ishiguro
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-06-18       Impact factor: 4.052

7.  Attitudes of cystic fibrosis patients and parents toward carrier screening and related reproductive issues.

Authors:  Sandra Janssens; Davit Chokoshvilli; Carmen Binst; Inge Mahieu; Lidewij Henneman; Anne De Paepe; Pascal Borry
Journal:  Eur J Hum Genet       Date:  2015-07-29       Impact factor: 4.246

Review 8.  Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.

Authors:  W Zhang; X Zhang; Y H Zhang; D C Strokes; A P Naren
Journal:  Drugs Today (Barc)       Date:  2016-04       Impact factor: 2.245

9.  Exploring the landscape of pathogenic genetic variation in the ExAC population database: insights of relevance to variant classification.

Authors:  Wei Song; Sabrina A Gardner; Hayk Hovhannisyan; Amanda Natalizio; Katelyn S Weymouth; Wenjie Chen; Ildiko Thibodeau; Ekaterina Bogdanova; Stanley Letovsky; Alecia Willis; Narasimhan Nagan
Journal:  Genet Med       Date:  2015-12-17       Impact factor: 8.822

10.  Personalised medicine for non-classic cystic fibrosis resulting from rare CFTR mutations.

Authors:  Matthew S McCravy; Nancy L Quinney; Deborah M Cholon; Susan E Boyles; Timothy J Jensen; Andrei A Aleksandrov; Scott H Donaldson; Peadar G Noone; Martina Gentzsch
Journal:  Eur Respir J       Date:  2020-07-30       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.